Pyramax - opinion on medicine for use outside EU
artesunate / pyronaridine
EU-M4allHuman
Overview
Pyramax is a medicine that contains the active substances pyronaridine tetraphosphate and artesunate. It is available as tablets (180 mg/60 mg) and as granules (60 mg/20 mg in each sachet).
Pyramax is used to treat uncomplicated malaria, caused by two types of malaria parasites, Plasmodium falciparum and Plasmodium vivax. ‘Uncomplicated’ means the disease does not involve severe, life-threatening symptoms. Pyramax tablets are used for adults and children weighing 20 kg or more and the granules are used for babies and children weighing between 5 and 20 kg.
The medicine can only be obtained with a prescription.
Pyramax is taken once a day for three days. The daily dose depends on the patient’s weight, and for tablets it ranges from one tablet a day for patients weighing between 20 and 24 kg to four tablets a day for patients over 65 kg.
Pyramax granules suspended in water are used for babies and children weighing from 5 kg to under 20 kg. The dose ranges from one sachet a day for babies and children weighing between 5 and under 8 kg to three sachets a day for children weighing between 15 and under 20 kg. For more information on how to use Pyramax, see the summary of product characteristics (SmPC).
Malaria is an infectious disease caused by Plasmodium parasites and spread through the bite of an infected mosquito.
The active substances in Pyramax act against P. falciparum and P.vivax species of the parasite. Artesunate is a derivative of the naturally occurring substance artemisinin. Although the exact way in which artemisinin antimalarials work is not fully understood, it is thought that they could work by forming toxic substances called ‘free radicals’ inside the parasite or by damaging calcium pumps that are important for the parasite to thrive.
Pyronaridine is thought to work by blocking a step in the parasite’s metabolism needed for its survival in the patient’s red blood cells.
There were three main studies in patients with uncomplicated P. falciparum malaria. Two studies, conducted in Africa and Asia, involved a total 2,543 adults and children weighing 20 kg and over and compared Pyramax tablets with other artemisinin combinations (artesunate plus mefloquine or artemether-lumefantrine). A third study, conducted in Africa and the Philippines using Pyramax granules involved a total of 535 children weighing between 5 kg and 25 kg compared Pyramax to artemether-lumefantrine.
One further main study involving a total of 456 adults and children weighing 20 kg and over was conducted in uncomplicated P. vivax malaria. This study, which was took place in Asia, compared Pyramax with chloroquine, a medicine widely used to treat P. vivax malaria.
Finally, another study compared Pyramax with artemether-lumefantrine for treating malaria that recurred over two malarial seasons. It involved a total of 1,686 West African patients, of which 393 patients taking Pyramax weighed between 5 and 20 kg.
The main measures of effectiveness were based on the number of patients whose blood was cleared of the malaria parasites, excluding those patients who got new infection during study.
Pyramax was effective in treating P. falciparum and P. vivax malaria, on average clearing parasites from the blood within one or two days.
Pyramax was also as effective as the comparator medicines in patients who were evaluated. Excluding patients with new infections, around 95% of patients treated with Pyramax in one P. falciparum study and 98% in another had no P. falciparum parasites in their blood after 42 days compared with around 97% and 99% seen with the comparator medicines. In addition, 94% of patients in the study of small children had no P. falciparum parasites in their blood after 42 days compared with 96% of the patients taking the comparator.
In uncomplicated P. vivax malaria, around 97% of patients taking Pyramax were cleared of P. vivax parasites after 28 days compared with 97% of patients treated with chloroquine.
Pyramax was also effective in the additional study in patients treated again when malaria recurred.
The most common side effects with Pyramax (seen in between 1 and 10 patients in 100) were headache, abnormal levels of white blood cells, anaemia (low red blood cell counts), increased platelet count, vomiting, abdominal pain (stomach ache), bradycardia (slow heart rate), increased levels of liver enzymes, and hypoglycaemia (low blood glucose levels). For the full list of all side effects reported with Pyramax, see the package leaflet.
Pyramax must not be used in patients with severe kidney problems. It must also not be taken by patients with severe liver disease or those with signs or symptoms of liver problems such as nausea, abdominal pain and yellowing of the eyes and skin (jaundice).
The CHMP noted that the World Health Organization recommends that artemisinin be used in combination with other medicines to reduce the risk of the parasites developing resistance.
Pyramax has been shown in clinical studies to be as effective as two other artemisinin combinations in treating the most dangerous parasite, P. falciparum, and as effective as chloroquine in treating P. vivax. With regard to the risks, the main concern was related to increases in levels of liver enzymes seen in some patients. To minimise the risk to the liver, Pyramax should not be used in patients with severe liver disease or in those with signs or symptoms of liver problems.
A risk management plan has been developed to ensure that Pyramax is used as safely as possible. Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Pyramax, including the appropriate precautions to be followed by healthcare professionals and patients.
The CHMP gave a positive scientific opinion on Pyramax on 16 February 2012. This opinion was given as part of its cooperation with the World Health Organization, whereby the CHMP provides opinions on medicines that are not intended for use in the EU but are needed to prevent or treat diseases of major public interest around the world.
Product information
Latest procedure affecting product information: IB/0029/G
15/06/2022
Product information documents contain:
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturer responsible for batch release
- Annex IIB - Recommendations to the opinion holder - conditions of use
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Pharmacotherapeutic group
AntimalarialsTherapeutic indication
For tablets and granules combined:
Pyramax tablets are indicated in the treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or by Plasmodium vivax in adults and children weighing 20 kg or more.
Pyramax Granules for oral suspension are indicated in the treatment of acute, uncomplicated malaria infection caused by Plasmodium falciparum or by Plasmodium vivax in children and infants weighing 5 kg to under 20 kg.
Consideration should be given to official guidance on the appropriate use of antimalarial agents.
Opinion details
Product details
- Name of medicine
- Pyramax
- EMA opinion number
- H-W-2319
- Opinion status
- Positive opinion
- Active substance
- artesunate
- pyronaridine
- International non-proprietary name (INN) or common name
- artesunate
- pyronaridine
- Therapeutic area (MeSH)
- Malaria
- Anatomical therapeutic chemical (ATC) code
- P01BF06
Publication details
- Opinion holder
- Shin Poong Pharmaceutical Co., Ltd.
748-31 Yoksam-Dong
Gangnam-Gu
Seoul 135-925
Korea - Date of opinion